Lexeo Therapeutics’ (LXEO) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Lexeo Therapeutics (NASDAQ:LXEO) in a research report sent to investors on Thursday morning,Benzinga reports.

LXEO has been the topic of a number of other research reports. Wall Street Zen upgraded Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. Raymond James Financial reiterated a “strong-buy” rating on shares of Lexeo Therapeutics in a research note on Tuesday, September 22nd. Leerink Partners reiterated an “outperform” rating and set a $15.00 price objective on shares of Lexeo Therapeutics in a research note on Wednesday, September 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Lexeo Therapeutics in a report on Wednesday. Finally, Chardan Capital upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Lexeo Therapeutics has a consensus rating of “Buy” and a consensus price target of $16.43.

Lexeo Therapeutics Stock Performance

Shares of LXEO stock traded down $0.04 during trading on Thursday, hitting $2.87. The company had a trading volume of 446,906 shares, compared to its average volume of 1,297,739. The firm has a market capitalization of $235.48 million, a P/E ratio of -2.50 and a beta of 1.64. The stock’s 50-day moving average price is $3.38 and its 200 day moving average price is $5.01. Lexeo Therapeutics has a one year low of $2.55 and a one year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). On average, research analysts anticipate that Lexeo Therapeutics will post -1.22 earnings per share for the current fiscal year.

Institutional Trading of Lexeo Therapeutics

Several large investors have recently bought and sold shares of the business. BlackRock Inc. acquired a new position in Lexeo Therapeutics during the 2nd quarter worth approximately $26,717,000. Montanova Capital LLC increased its holdings in shares of Lexeo Therapeutics by 410.7% during the second quarter. Montanova Capital LLC now owns 6,384,200 shares of the company’s stock worth $29,718,000 after buying an additional 5,134,200 shares in the last quarter. Jupiter Topco LLC acquired a new position in shares of Lexeo Therapeutics during the second quarter worth $18,409,000. Affinity Asset Advisors LLC lifted its stake in shares of Lexeo Therapeutics by 57.8% in the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock valued at $28,988,000 after acquiring an additional 1,850,211 shares during the last quarter. Finally, ADAR1 Capital Management LLC acquired a new stake in shares of Lexeo Therapeutics during the 2nd quarter valued at $7,289,000. 60.67% of the stock is owned by institutional investors and hedge funds.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc. is a clinical-stage biotechnology company developing gene therapies for inherited cardiovascular and other serious diseases. Its research focuses on using genetic medicines to address conditions caused by specific gene mutations. The company’s investigational programs include LX2006, a gene therapy being studied for Friedreich ataxia cardiomyopathy, and other candidates targeting genetically defined heart diseases. These therapies remain in development and are not established commercial products.